Skip to main content
Premium Trial:

Request an Annual Quote

Nanosphere, Lilly Ink PGx Test Alliance

NEW YORK (GenomeWeb News) – Nanosphere today said that has signed an agreement with Eli Lilly to develop pharmacogenetic assays that Lilly will use in its drug development efforts.

The Northbrook, Ill.-based molecular diagnostics developer said that it would develop the assays to run on its new Verigene SP system, which is a sample-to-result, bench-top, molecular diagnostics instrument. It is a random access system that does not require PCR amplification, said Nanosphere.

Terms of the alliance have not been disclosed.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.